A cancer pharmaceutical startup that opened a new headquarters in Cambridge earlier this year is already in need of more space.

Blueprint Medicines moved into its 100K SF headquarters at 45 Sidney St. in spring 2018, but the company is now taking the entire building with a 40K SF expansion. The company’s newest least began Sept. 19, according to a filing with the Securities and Exchange Commission. The space Blueprint is expanding into was previously occupied by Novartis.

“Blueprint’s expansion points to the strength of Cambridge’s life science market and continued growth among biotech companies of all sizes,” Hunneman Director of Research Liz Berthelette said. “Blueprint’s expansion also points to the strength and maturity of Mid Cambridge’s Sidney Street lab corridor.”

Blueprint will initially pay about $82/SF for the new space, according to the filing. The expansion comes at a time when available office and lab space in the area is extremely hard to come by, and technology and lab tenants are often competing for the same space. Facebook leased 130K SF at 100 Binney St., an Alexandria Real Estate Equities property also home to biotech startups and Bristol-Myers Squibb.

Philips North America is moving its headquarters to Cambridge Crossing to a building that was also built to accommodate labs.

Blueprint Medicines did not immediately respond to a request for comment.